Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Multiple Cancer Types
This open-label, phase Ib / II study of surufatinib in combination with tislelizumab will evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors. The study consists of 2 parts - dose finding (Part 1) and dose expansion (Part 2).
Miscellaneous, Phase I